Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly

Clinics in Geriatric Medicine

Volumn 32, Issue 1, 2016, Pages 155-173

  Klepin, Heidi D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Elderly; Management; Myelodysplasia; Older; Treatment

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; AZACITIDINE; CYTARABINE; DECITABINE; ERYTHROPOIETIN; LENALIDOMIDE; PLACEBO; RETINOIC ACID;

5Q- SYNDROME; ACUTE MYELOBLASTIC LEUKEMIA; AGING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; BLOOD ANALYSIS; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CYTOGENETICS; CYTOPENIA; DRUG MEGADOSE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; AGED; COMORBIDITY; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; GERIATRIC ASSESSMENT; LEUKEMIA, MYELOID, ACUTE; LIFE EXPECTANCY; MYELODYSPLASTIC SYNDROMES; RISK FACTOR; SOCIAL SUPPORT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; GERIATRIC ASSESSMENT; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIFE EXPECTANCY; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; SOCIAL SUPPORT;

EID: 84960380274     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2015.08.010     Document Type: Review

References (68)

1. Efficace F., Gaidano G., Breccia M., et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol 2015, 168:361-370.
2. Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008, 112:45-52.
3. SEER cancer statistics review 1975-2009. 2012. Available at: . Accessed July 21, 2015. http://www.seer.cancer.gov.
4. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
5. Greenberg P.L., Tuechler H., Schanz J., et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
6. Voso M.T., Fenu S., Latagliata R., et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013, 31:2671-2677.
7. Della Porta M.G., Malcovati L., Strupp C., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96:441-449.
8. Daver N., Naqvi K., Jabbour E., et al. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol 2014, 89:509-516.
9. Naqvi K., Garcia-Manero G., Sardesai S., et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011, 29:2240-2246.
10. Balleari E., Salvetti C., Del Corso L., et al. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes. Leuk Res 2015, 39(8):846-852.
11. Fega K.R., Abel G.A., Motyckova G., et al. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol 2015, 6(4):288-298.
12. Deschler B., Ihorst G., Platzbecker U., et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013, 98:208-216.
13. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
14. Moyo V., Lefebvre P., Duh M.S., et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008, 87:527-536.
15. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
16. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
17. Kornblith A.B., Herndon J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441-2452.
18. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
19. Xicoy B., Jimenez M.J., Garcia O., et al. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma 2014, 55:1300-1303.
20. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
21. Fenaux P., Giagounidis A., Selleslag D., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118:3765-3776.
22. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
23. Sibon D., Cannas G., Baracco F., et al. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol 2012, 156:619-625.
24. Koreth J., Pidala J., Perez W.S., et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013, 31:2662-2670.
25. Muffly L.S., Kocherginsky M., Stock W., et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica 2014, 99(8):1373-1379.
26. American Cancer Society. 2009. Available at: . Accessed July 21, 2015. http://wwwcancerorg/docroot/home/indexasp.
27. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
28. Juliusson G. Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood 2011, 117:3473-3474.
29. Kantarjian H., Ravandi F., O'Brien S., et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010, 116:4422-4429.
30. Oran B., Weisdorf D.J. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012, 97:1916-1924.
31. Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
32. Lowenberg B., Zittoun R., Kerkhofs H., et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989, 7:1268-1274.
33. Wetzler M., Mrozek K., Kohlschmidt J., et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica 2014, 99:308-313.
34. Farag S.S., Archer K.J., Mrozek K., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
35. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
36. Rao A.V., Valk P.J., Metzeler K.H., et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009, 27:5580-5586.
37. Scholl S., Theuer C., Scheble V., et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol 2008, 80:208-215.
38. Leith C.P., Kopecky K.J., Godwin J., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-3329.
39. Castaigne S., Pautas C., Terre C., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379:1508-1516.
40. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
41. Baer M.R., George S.L., Dodge R.K., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002, 100:1224-1232.
42. Burnett A.K., Russell N.H., Hills R.K., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012, 30:3924-3931.
43. Lowenberg B., Ossenkoppele G.J., van Putten W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
44. Lowenberg B., Suciu S., Archimbaud E., et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998, 16:872-881.
45. Stone R.M., Berg D.T., George S.L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995, 332:1671-1677.
46. Tilly H., Castaigne S., Bordessoule D., et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990, 8:272-279.
47. Pautas C., Merabet F., Thomas X., et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010, 28:808-814.
48. Serve H., Krug U., Wagner R., et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013, 31:3110-3118.
49. Burnett A.K., Milligan D., Prentice A.G., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
50. Kantarjian H.M., Thomas X.G., Dmoszynska A., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
51. Dombret H., Seymour J.F., Butrym A., et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015, 126:291-299.
52. Stone R.M., Berg D.T., George S.L., et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001, 98:548-553.
53. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994, 331:896-903.
54. Hahn T., McCarthy P.L., Hassebroek A., et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013, 31:2437-2449.
55. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.
56. Lo-Coco F., Avvisati G., Vignetti M., et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369:111-121.
57. Krug U., Rollig C., Koschmieder A., et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010, 376:2000-2008.
58. Rollig C., Thiede C., Gramatzki M., et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010, 116:971-978.
59. Wheatley K., Brookes C.L., Howman A.J., et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009, 145:598-605.
60. Etienne A., Esterni B., Charbonnier A., et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007, 109:1376-1383.
61. Giles F.J., Borthakur G., Ravandi F., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136:624-627.
62. Malfuson J.V., Etienne A., Turlure P., et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008, 93:1806-1813.
63. Klepin H.D., Geiger A.M., Tooze J.A., et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013, 121:4287-4294.
64. Wedding U., Rohrig B., Klippstein A., et al. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006, 132:665-671.
65. Klepin H.D., Geiger A.M., Tooze J.A., et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 2011, 59:1837-1846.
66. Sherman A.E., Motyckova G., Fega K.R., et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 2013, 37:998-1003.
67. Alibhai S.M., Breunis H., Timilshina N., et al. Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. J Geriatr Oncol 2015, 6(4):262-271.
68. Mohamedali H., Breunis H., Timilshina N., et al. Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res 2012, 36:1241-1248.